NYSE:BHVN

Biohaven Pharmaceutical Holding Company Stock News

Healthcare > Biotechnology

Buy BHVN

*Your capital is at risk

$10.81

+0.680 (+6.71%)

At Close: Jun 03, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

01:24pm, Monday, 02'nd Jun 2025

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN). Such investors are advised

Protect Your Investment: Contact Levi & Korsinsky About the Biohaven Ltd. (BHVN) Investigation

01:00pm, Sunday, 01'st Jun 2025

NEW YORK, NY / ACCESS Newswire / June 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

10:00am, Sunday, 01'st Jun 2025

NEW YORK , June 1, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN).

BHVN Investor Notice: Levi & Korsinsky Investigates Biohaven Ltd. for Securities Law Violations

11:00am, Friday, 30'th May 2025

NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.

Investors in Biohaven Ltd. (BHVN) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today

07:15am, Thursday, 29'th May 2025

NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.

Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor

07:01am, Thursday, 29'th May 2025

BHV-8000 is a first-in-clinic, brain-penetrant, and selective inhibitor of TYK2 and JAK1 kinases — a novel investigational therapy with the potential to treat the neuroinflammation and immune dysreg

Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN)

03:00pm, Wednesday, 28'th May 2025

Optimized subcutaneous (SC) administration of BHV-1400 achieved rapid, deep, selective, and sustained lowering of Gd-IgA1, differentiating Biohaven's leading TRAP degrader for IgAN from the complement

Lost Money on Biohaven Ltd. (BHVN)? Contact Levi & Korsinsky About Investigation

10:15am, Wednesday, 28'th May 2025

NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

09:00am, Wednesday, 28'th May 2025

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN).

Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors

07:30am, Wednesday, 28'th May 2025

BHV-1510, a highly differentiated Trop2 ADC incorporating the proprietary TopoIx payload, demonstrates early clinical activity and favorable safety profile in Phase 1 study as a monotherapy and in co

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by